A randomized, double-blind study of zinpentraxin alfa in patients with myelofibrosis who were previously treated with or ineligible for ruxolitinib: stage 2 of a phase II trial

被引：1
|
作者：
Verstovsek, Srdan [1 ,12 ]
Talpaz, Moshe [2 ]
Wadleigh, Martha [3 ]
Isidori, Alessandro [4 ]
te Boekhorst, Peter [5 ]
Savona, Michael R. [6 ]
Bose, Prithviraj [1 ]
Pozdnyakova, Olga [7 ]
Mesa, Ruben [8 ,13 ]
El-Galaly, Tarec C. [9 ,14 ]
O'Sullivan, Jennifer [10 ]
Gamel, Katia [9 ]
Higgins, Brian [11 ]
Katakam, Sudhakar [9 ]
Todorov, Boyan [9 ]
Trunzer, Kerstin [9 ]
Harrison, Claire N. [10 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[2] Univ Michigan, Michigan Med, Ann Arbor, MI USA
[3] Dana Farber Canc Inst, Boston, MA USA
[4] AORMN Hosp, Hematol & Stem Cell Transplant Ctr, Pesaro, Italy
[5] Erasmus MC, Rotterdam, Netherlands
[6] Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Nashville, TN USA
[7] Harvard Med Sch, Brigham & Womens Hosp, Boston, MA USA
[8] UT Hlth San Antonio MD Anderson, Mays Canc Ctr, San Antonio, TX USA
[9] F Hoffmann La Roche Ltd, Basel, Switzerland
[10] Guys & St Thomas NHS Fdn Trust, London, England
[11] Genentech Inc, South San Francisco, CA USA
[12] Kartos Therapeut, Redwood City, CA USA
[13] Wake Forest Baptist Comprehens Canc Ctr, Winston Salem, NC USA
[14] Aalborg Univ Hosp, Dept Hematol, Aalborg, Denmark
来源：
HAEMATOLOGICA | 2024年 / 109卷 / 06期
关键词：
BONE-MARROW FIBROSIS; PROGNOSTIC IMPACT; PATHOGENESIS;
D O I：
10.3324/haematol.2023.284410
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1977 / 1983
页数：7
相关论文
共 50 条
  • [1] Safety and efficacy of zinpentraxin alfa as monotherapy or in combination with ruxolitinib in myelofibrosis: stage I of a phase II trial
    Verstovsek, Srdan
    Foltz, Lynda
    Gupta, Vikas
    Hasserjian, Robert
    Manshouri, Taghi
    Mascarenhas, John
    Mesa, Ruben
    Pozdnyakova, Olga
    Ritchie, Ellen
    Veletic, Ivo
    Gamel, Katia
    Hamidi, Habib
    Han, Lyrialle
    Higgins, Brian
    Trunzer, Kerstin
    Uguen, Marianne
    Wang, Dao
    El-Galaly, Tarec Christoffer
    Todorov, Boyan
    Gotlib, Jason
    HAEMATOLOGICA, 2023, 108 (10) : 2730 - 2742
  • [2] A randomized, double-blind, placebo-controlled phase 3 study of parsaclisib plus ruxolitinib in patients with myelofibrosis who have suboptimal response to ruxolitinib
    Yacoub, Abdulraheem
    Stouffs, Michael
    Zhou, Feng
    Assad, Albert
    BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 : 112 - 113
  • [3] A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Parsaclisib Plus Ruxolitinib in Patients with Myelofibrosis Who Have Suboptimal Response to Ruxolitinib.
    Yacoub, Abdulraheem
    Stouffs, Michael
    Zhou, Feng
    Assad, Albert
    CANCER RESEARCH, 2021, 81 (13)
  • [4] Phase 1/2 trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with ruxolitinib
    Gerds, Aaron T.
    Tauchi, Tetsuzo
    Ritchie, Ellen
    Deininger, Michael
    Jamieson, Catriona
    Mesa, Ruben
    Heaney, Mark
    Komatsu, Norio
    Minami, Hironobu
    Su, Yun
    Shaik, Naveed
    Zhang, Xiaoxi
    DiRienzo, Christine
    Zeremski, Mirjana
    Chan, Geoffrey
    Talpaz, Moshe
    LEUKEMIA RESEARCH, 2019, 79 : 38 - 44
  • [5] Phase III randomized, double-blind, active-controlled study of momelotinib versus ruxolitinib in patients with myelofibrosis.
    Winton, Elliott F.
    Devos, Timothy
    Oh, Stephen T.
    Platzbecker, Uwe
    Wadleigh, Martha
    Jun, Susie
    Lee, Peter
    Deng, Wei
    Gupta, Vikas
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [6] ReTHINK: A randomized, double-blind, placebo controlled, multicenter, phase 3 study of ruxolitinib in early myelofibrosis patients.
    Passamonti, Francesco
    Kiladjian, Jean-Jacques
    Vannucchi, Alessandro M.
    Reiter, Andreas
    Bharathy, Savita
    Iommazzo, Dana
    Stalbovskaya, Viktoriya
    Gopalakrishna, Prashanth
    Mesa, Ruben A.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [7] Quantitative Analysis of Bone Marrow Features Highlights Heterogeneity in Myelofibrosis Patients Treated with Zinpentraxin Alfa in a Phase II Clinical Study
    Ryou, Hosuk
    Sirinukunwattana, Korsuk
    Wood, Ruby
    Aberdeen, Alan
    Rittscher, Jens
    Weinberg, Olga
    Hasserjian, Robert
    Pozdnyakova, Olga
    Peale, Frank
    Higgins, Brian
    Lundberg, Pontus
    Trunzer, Kerstin
    Harrison, Claire N.
    Royston, Daniel
    BLOOD, 2023, 142
  • [8] Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study
    Xu, Rui-Hua
    Li, Jin
    Bai, Yuxian
    Xu, Jianming
    Liu, Tianshu
    Shen, Lin
    Wang, Liwei
    Pan, Hongming
    Cao, Junning
    Zhang, Dongsheng
    Fan, Songhua
    Hua, Ye
    Su, Weiguo
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2017, 10 : 1 - 8
  • [9] Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study
    Rui-Hua Xu
    Jin Li
    Yuxian Bai
    Jianming Xu
    Tianshu Liu
    Lin Shen
    Liwei Wang
    Hongming Pan
    Junning Cao
    Dongsheng Zhang
    Songhua Fan
    Ye Hua
    Weiguo Su
    Journal of Hematology & Oncology, 10
  • [10] PHASE 3 RANDOMIZED TRIAL OF MOMELOTINIB VERSUS BEST AVAILABLE THERAPY IN PATIENTS WITH MYELOFIBROSIS PREVIOUSLY TREATED WITH RUXOLITINIB: RESULTS OF THE SIMPLIFY-2 STUDY
    Verstovsek, S.
    Vannucchi, A. M.
    Platzbecker, U.
    Cervantes, F.
    Gupta, V.
    Lavie, D.
    Passamonti, F.
    Winton, E. F.
    Dong, H.
    Kawashima, J.
    Maltzman, J. D.
    Kiladjian, J-J.
    Harrison, C. N.
    HAEMATOLOGICA, 2017, 102 : 320 - 321
12345